Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 12:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 2,672 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo oral capsules Clear all
Completed Phase 2 Interventional Results available

BI 671800 in Asthmatic Patients on Inhaled Corticosteroids

NCT01103349
View directory record Official record
Conditions
Asthma
Interventions
BI 671800, Placebo, Montelukast
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
6
States / cities
Denver, Colorado • North Dartmouth, Massachusetts • Plymouth, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Oct 15, 2026, 12:23 AM EDT
Completed Phase 3 Interventional Results available

Aspirin for Exercise in Multiple Sclerosis (ASPIRE)

NCT03824938
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Aspirin 650mg Oral Capsule, Acetaminophen Tablet 650mg, Placebo
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 27, 2023 · Synced Oct 15, 2026, 12:23 AM EDT
Completed Phase 3 Interventional Results available

Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®

NCT01696058
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium, Placebo matching Olodaterol, Olodaterol
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
1,137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
94
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 82 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2014 · Synced Oct 15, 2026, 12:23 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia

NCT02104752
View directory record Official record
Conditions
Schizophrenia, Cognition, Psychosis
Interventions
Curcumin, Placebo
Drug
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Oct 15, 2026, 12:23 AM EDT
Not listed Phase 1 Interventional

A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's

NCT06309147
View directory record Official record
Conditions
Parkinson Disease
Interventions
BMS-9894923
Drug
Lead sponsor
Allyx Therapeutics
Industry
Eligibility
50 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 15, 2026, 12:23 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants

NCT06139055
View directory record Official record
Conditions
Healthy Volunteers
Interventions
GSBR-1290 (Capsule/Tablet), GSBR-1290, Placebo, Placebo (Capsule/Tablet)
Drug
Lead sponsor
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Miami, Florida • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 15, 2024 · Synced Oct 15, 2026, 12:23 AM EDT
Completed Phase 1 Interventional

TAK-875 Glimepiride Drug-Interaction Study

NCT01496443
View directory record Official record
Conditions
Pharmacokinetics
Interventions
TAK-875 and Glimepiride
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 68 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2012 · Synced Oct 15, 2026, 12:23 AM EDT
Terminated Phase 4 Interventional Results available

Quality of Life in Patients With Statin-Associated Myopathy

NCT00850460
View directory record Official record
Conditions
Statin Adverse Reaction
Interventions
Statins, Placebo
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
40 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Oct 15, 2026, 12:23 AM EDT
Completed Phase 3 Interventional Results available

Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

NCT02009163
View directory record Official record
Conditions
Binge Eating Disorder
Interventions
Lisdexamfetamine dimesylate, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
39
States / cities
Fort Myers, Florida • Lauderhill, Florida • Leesburg, Florida + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 15, 2026, 12:23 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff

NCT03110133
View directory record Official record
Conditions
Clostridium Difficile Infection Recurrence
Interventions
Full Spectrum Microbiota, Placebo
Drug
Lead sponsor
Finch Research and Development LLC.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
54
States / cities
Scottsdale, Arizona • Los Angeles, California • Murrieta, California + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Oct 15, 2026, 12:23 AM EDT
Completed Phase 1 Interventional

A Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Participants With Major Depressive Disorder

NCT03374475
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
JNJ-42847922 20mg, JNJ-42847922 40mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
San Diego, California • San Marcos, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 15, 2026, 12:23 AM EDT
Recruiting Phase 2 Interventional

Zinc as an Adjunctive Therapy for Cervical Dystonia

NCT07140874
View directory record Official record
Conditions
Cervical Dystonia
Interventions
Zinc citrate, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 89 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 15, 2026, 12:23 AM EDT
Recruiting Phase 2 Interventional

New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia

NCT06944145
View directory record Official record
Conditions
BPH (Benign Prostatic Hyperplasia), Lower Urinary Track Symptoms
Interventions
raloxifene, Finasteride
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 15, 2026, 12:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Cardiac Safety of a Single Dose of AL-335 Administered on a Background of Simeprevir and Odalasvir and of Repeated Doses of Odalasvir Administered Alone in Healthy Participants

NCT03155893
View directory record Official record
Conditions
Healthy
Interventions
ODV Placebo (Matching 25 mg ODV), ODV Placebo (Matching 200 mg ODV), ODV Placebo (Matching 125 mg ODV), ODV Placebo (Matching 100 mg ODV), SMV Placebo (Matching 150 mg SMV), AL-335 Placebo (matching 1200 mg AL-335), Moxifloxacin Placebo (matching 400 mg moxifloxacin), ODV 25 mg, ODV 200 mg, ODV 125 mg, ODV 100 mg, SMV 150 mg, AL-335 1200 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 15, 2026, 12:23 AM EDT
Recruiting Phase 3 Interventional

Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis

NCT06950385
View directory record Official record
Conditions
Familial Adenomatous Polyposis (FAP)
Interventions
eRapa (encapsulated rapamycin), Placebo
Drug
Lead sponsor
Rapamycin Holdings Inc.
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
18
States / cities
Arcadia, California • New Haven, Connecticut • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 15, 2026, 12:23 AM EDT
Completed Phase 2 Interventional Results available

A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone

NCT00265317
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
erlotinib, sunitinib, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
18
States / cities
Birmingham, Alabama • Mobile, Alabama • Antioch, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Oct 15, 2026, 12:23 AM EDT
Completed Phase 1 Interventional

Study of Dapansutrile Capsules in Heart Failure

NCT03534297
View directory record Official record
Conditions
Systolic Heart Failure
Interventions
dapansutrile capsules, Placebo capsules
Drug
Lead sponsor
Olatec Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Oct 15, 2026, 12:23 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Trial of Indomethacin in Chronic Pancreatitis

NCT04207060
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
Indomethacin, Placebo, Endoscopy for Pancreatic Function Testing
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 60 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Rochester, Minnesota • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Oct 15, 2026, 12:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Gut-brain Axis in Food Reward and Alcohol Consumption

NCT01902069
View directory record Official record
Conditions
Impulsivity, Alcohol Consumption
Interventions
Phospholean, Placebo
Dietary Supplement
Lead sponsor
Yale University
Other
Eligibility
21 Years to 45 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 15, 2026, 12:23 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of Vanoxerine for the Conversion of Subjects With Recent Onset Atrial Fibrillation or Flutter to Normal Sinus Rhythm

NCT02454283
View directory record Official record
Conditions
Atrial Fibrillation or Flutter
Interventions
Vanoxerine HCl, Placebo
Drug
Lead sponsor
Laguna Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
4
States / cities
Littleton, Colorado • Washington D.C., District of Columbia • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Oct 15, 2026, 12:23 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Oral Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-104)

NCT05571345
View directory record Official record
Conditions
Recreational Drug Use
Interventions
PF614, Oxycodone Hydrochloride 40 mg, Placebo
Drug
Lead sponsor
Ensysce Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 15, 2026, 12:23 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients

NCT02515331
View directory record Official record
Conditions
Patients, Resistant Hypertension
Interventions
LHW090, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 85 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
7
States / cities
Birmingham, Alabama • North Hollywood, California • Atlantis, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 15, 2026, 12:23 AM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors

NCT07656727
View directory record Official record
Conditions
Obesity and Cardiovascular Risk
Interventions
Oral BGE-102, Oral Placebo Matching BGE-102
Drug
Lead sponsor
BioAge Labs, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
16
States / cities
Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 15, 2026, 12:23 AM EDT
Completed Phase 2 Interventional

YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)

NCT04000737
View directory record Official record
Conditions
Advanced Hepatocellular Carcinoma
Interventions
Sorafenib+YIV-906, Sorafenib+placebo
Drug
Lead sponsor
Yiviva Inc.
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Flushing, New York • Lake Success, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Oct 15, 2026, 12:23 AM EDT